tiprankstipranks
Advertisement
Advertisement

MNPR Stock Latest News

BTIG’s Mukherjee Initiates Buy on Monopar Therapeutics, Citing Emerging Head & Neck Cancer Data and Favorable Risk‑Reward Setup
RatingsBTIG’s Mukherjee Initiates Buy on Monopar Therapeutics, Citing Emerging Head & Neck Cancer Data and Favorable Risk‑Reward Setup
8d ago
MNPR
Maldonado Reiterates Buy on Monopar as ALXN1840 NDA Progress and Robust Clinical Data Drive Price Target Increase from $105 to $125
PremiumRatings
Maldonado Reiterates Buy on Monopar as ALXN1840 NDA Progress and Robust Clinical Data Drive Price Target Increase from $105 to $125
10d ago
MNPR
Monopar price target raised to $125 from $105 at H.C. Wainwright
PremiumThe Fly
Monopar price target raised to $125 from $105 at H.C. Wainwright
10d ago
MNPR
Monopar Begins Rolling FDA NDA Submission for ALXN1840
PremiumCompany Announcements
Monopar Begins Rolling FDA NDA Submission for ALXN1840
10d ago
8K
MNPR
Monopar Therapeutics initiates rolling ALXN1840 NDA submission to FDA
PremiumThe Fly
Monopar Therapeutics initiates rolling ALXN1840 NDA submission to FDA
10d ago
MNPR
Monopar Therapeutics price target raised to $117 from $104 at BTIG
PremiumThe FlyMonopar Therapeutics price target raised to $117 from $104 at BTIG
1M ago
MNPR
Monopar Wins FDA Rare Pediatric Disease Designation
Premium
Company Announcements
Monopar Wins FDA Rare Pediatric Disease Designation
1M ago
8K
MNPR
Monopar Therapeutics receives Rare Pediatric Disease designation for ALXN1840
Premium
The Fly
Monopar Therapeutics receives Rare Pediatric Disease designation for ALXN1840
1M ago
MNPR
Monopar Therapeutics price target raised to $117 from $104 at BTIG
PremiumThe Fly
Monopar Therapeutics price target raised to $117 from $104 at BTIG
1M ago
MNPR
Monopar Highlights Positive Phase 3 Wilson Disease Data
PremiumCompany Announcements
Monopar Highlights Positive Phase 3 Wilson Disease Data
1M ago
8K
MNPR
Monopar Therapeutics announces new FoCus trial analyses
PremiumThe Fly
Monopar Therapeutics announces new FoCus trial analyses
1M ago
MNPR
Monopar Shareholders Approve Directors, Pay and Incentive Plan
PremiumCompany Announcements
Monopar Shareholders Approve Directors, Pay and Incentive Plan
1M ago
8K
MNPR
Monopar Therapeutics management to meet virtually with Piper Sandler
PremiumThe FlyMonopar Therapeutics management to meet virtually with Piper Sandler
1M ago
MNPR
Monopar: Buy Rating Reiterated as ALXN1840 Data Underpin Valuation and $104 Price Target Maintained
Premium
Ratings
Monopar: Buy Rating Reiterated as ALXN1840 Data Underpin Valuation and $104 Price Target Maintained
2M ago
MNPR
Monopar Therapeutics presents ALXN1840-WD-205 data at EASL
Premium
The Fly
Monopar Therapeutics presents ALXN1840-WD-205 data at EASL
2M ago
MNPR
Monopar Highlights Phase 2 ALXN1840 Data in Wilson Disease
PremiumCompany Announcements
Monopar Highlights Phase 2 ALXN1840 Data in Wilson Disease
2M ago
8K
MNPR
Monopar Showcases ALXN1840 Phase 2 Wilson Disease Data
PremiumCompany Announcements
Monopar Showcases ALXN1840 Phase 2 Wilson Disease Data
2M ago
8K
MNPR
Monopar Buy Rating Reiterated on Advancing ALXN1840 Profile and De-Risked Regulatory Path; $104 Price Target Unchanged
PremiumRatings
Monopar Buy Rating Reiterated on Advancing ALXN1840 Profile and De-Risked Regulatory Path; $104 Price Target Unchanged
3M ago
MNPR
Monopar Highlights Strong Phase 3 Data for ALXN1840
PremiumCompany Announcements
Monopar Highlights Strong Phase 3 Data for ALXN1840
3M ago
8K
MNPR
ALXN1840 Poised to Redefine Wilson Disease Treatment Standards: Phase 3 Success, De-Risked Profile, and Buy Rating Justification
PremiumRatingsALXN1840 Poised to Redefine Wilson Disease Treatment Standards: Phase 3 Success, De-Risked Profile, and Buy Rating Justification
3M ago
MNPR
Monopar announces new analyses from Phase 3 FoCus trial of ALXN1840
Premium
The Fly
Monopar announces new analyses from Phase 3 FoCus trial of ALXN1840
3M ago
MNPR
Buy Rating Reaffirmed on ALXN1840 De‑Risking, 2027 Approval Potential, and Strong Cash Runway
Premium
Ratings
Buy Rating Reaffirmed on ALXN1840 De‑Risking, 2027 Approval Potential, and Strong Cash Runway
4M ago
MNPR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >